Neoadjuvant chemo-immunotherapy

DRUG4 trials

Conditions

Adjuvant TherapyGastric / Gastroesophageal Junction AdenocarcinomaGastroesophageal JunctionLocally Advanced Sinonasal CarcinomaMesothelioma; PleuraNeoadjuvant ChemoimmunotherapyPleural Epithelioid MesotheliomaStage III Non-small Cell Lung Cancer

Phase 1

NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study

RecruitingNCT07121374

University Hospital, AntwerpMesothelioma; Pleura, Neoadjuvant Chemoimmunotherapy, Pleural Epithelioid Mesothelioma

Start: 2025-07-22End: 2029-07-31Target: 37Updated: 2025-08-13

Phase 2

Study of Tislelizumab for Locally Advanced Non-Small Cell Lung Cancer Following Neoadjuvant Chemotherapy Plus Tislelizumab ± Bevacizumab and Definitive Concurrent Chemoradiation Therapy

RecruitingNCT05468242

Sun Yat-sen UniversityStage III Non-small Cell Lung Cancer

Start: 2022-01-01End: 2024-12-30Target: 116Updated: 2024-10-30

Neoadjuvant Docetaxel, Cisplatin, and Dual Immunotherapy for Sinonasal Carcinoma

Not yet recruitingNCT07645846

Sun Yat-sen UniversityLocally Advanced Sinonasal Carcinoma

Start: 2026-07-31End: 2030-08-01Target: 23Updated: 2026-06-25

Unknown Phase

Pucotenlimab Combined With Chemotherapy as Perioperative Treatment for Locally Advanced Gastroesophageal Junction Carcinoma

Not yet recruitingNCT07092449

Tang-Du HospitalAdjuvant Therapy, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction +1

Start: 2025-08-01End: 2027-12-31Target: 30Updated: 2025-07-29

Related Papers

A phase II, two-cohort study of neoadjuvant chemotherapy plus tislelizumab ± bevacizumab followed by hypofractionated radiotherapy, concurrent chemotherapy, and consolidative immunotherapy in locally advanced non-small cell lung cancer (GASTO-1086).